BioSyent, Inc. (RX.V)
17.15
+0.23
(+1.36%)
CAD |
TSXV |
Oct 09, 16:00
BioSyent Gross Profit Margin (Quarterly) : 65.02% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.02% |
| March 31, 2026 | 69.59% |
| December 31, 2025 | 74.65% |
| September 30, 2025 | 74.17% |
| June 30, 2025 | 75.64% |
| March 31, 2025 | 74.01% |
| December 31, 2024 | 78.65% |
| September 30, 2024 | 77.12% |
| June 30, 2024 | 77.69% |
| March 31, 2024 | 77.96% |
| December 31, 2023 | 79.57% |
| September 30, 2023 | 78.35% |
| June 30, 2023 | 80.19% |
| March 31, 2023 | 80.59% |
| December 31, 2022 | 80.92% |
| September 30, 2022 | 81.16% |
| June 30, 2022 | 80.87% |
| March 31, 2022 | 78.02% |
| December 31, 2021 | 79.12% |
| September 30, 2021 | 77.02% |
| June 30, 2021 | 76.56% |
| March 31, 2021 | 77.30% |
| December 31, 2020 | 74.85% |
| September 30, 2020 | 75.46% |
| June 30, 2020 | 75.44% |
| Date | Value |
|---|---|
| March 31, 2020 | 77.07% |
| December 31, 2019 | 76.41% |
| September 30, 2019 | 73.97% |
| June 30, 2019 | 78.03% |
| March 31, 2019 | 77.59% |
| December 31, 2018 | 75.29% |
| September 30, 2018 | 77.18% |
| June 30, 2018 | 76.28% |
| March 31, 2018 | 75.82% |
| December 31, 2017 | 75.48% |
| September 30, 2017 | 76.74% |
| June 30, 2017 | 74.42% |
| March 31, 2017 | 78.22% |
| December 31, 2016 | 76.20% |
| September 30, 2016 | 76.92% |
| June 30, 2016 | 79.08% |
| March 31, 2016 | 80.52% |
| December 31, 2015 | 80.44% |
| September 30, 2015 | 76.32% |
| June 30, 2015 | 79.44% |
| March 31, 2015 | 78.56% |
| December 31, 2014 | 78.26% |
| September 30, 2014 | 76.82% |
| June 30, 2014 | 79.37% |
| March 31, 2014 | 77.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| HLS Therapeutics, Inc. | 42.90% |
| Bausch Health Cos., Inc. | 65.04% |
| Cipher Pharmaceuticals, Inc. | 65.58% |
| Revive Therapeutics Ltd. | -- |
| Knight Therapeutics, Inc. | 38.94% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 23.52% |
| Return on Assets | 18.71% |
| Return on Invested Capital | 22.34% |
| Profit Margin (Quarterly) | 14.34% |
| Operating Margin (Quarterly) | 19.78% |
| Return on Net Operating Assets | 35.58% |